Standard BioTools Inc. (LAB)

The stock price of Standard BioTools has been influenced by analyst price target adjustments, preliminary Q4 and full year 2025 revenue announcement, completion of SomaLogic sale, Q4 and full year 2025 financial results, Nasdaq non-compliance notice, and Q1 2026 financial results. Shares have lost approximately 27% since the beginning of the year.

Demand for Standard BioTools' products and services can be influenced by capital-constrained end-markets, project funding, pharmaceutical customer demand, and instrument quality and uptime. Demand can fluctuate based on research funding cycles, capital expenditure budgets of its customers, and the specific needs of the pharmaceutical industry, rather than a strict calendar-based seasonality.

Standard BioTools, Inc. is a life science tools company focused on proteomics and genomics, operating in the Healthcare sector under the Medical Devices & Instruments industry. It develops, manufactures, and sells technologies that enable insights into health and disease using mass cytometry and microfluidics technologies. Its major products and platforms include analytical mass cytometry systems, automated genomic analysis instruments, Biomark™ X9 System, CyTOF XT system, Hyperion XTi Imaging System, SomaScan platform, and a range of consumables and services. The company serves a global clientele including academic research institutions, translational research and medical centers, biopharmaceutical, biotechnology, and plant and animal research companies.

Standard BioTools has a global presence with operations in the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. It maintains offices and facilities in North America (Canada and USA), Europe (France, United Kingdom, Netherlands, Germany, and Italy), and Asia (China, Singapore, and Japan).

Standard BioTools is generally recognized as a key innovator in life science research, offering tools that accelerate health breakthroughs. The company is known for its focus on pure science and innovation, with cutting-edge products designed to provide reliable and repeatable insights in health and disease research. Employee reviews indicate a collaborative culture and opportunities to learn, but also mention areas for improvement such as overall satisfaction, trust in colleagues, and a sense of belonging, along with past issues of chaotic management and changing priorities.

Major institutional investors hold a commanding majority of Standard BioTools' shares, reflecting significant confidence in the company's strategic direction and future growth prospects. Key institutional shareholders include Casdin Capital, LLC, Viking Global Investors LP, and BlackRock, Inc. Institutional investors represent a significant portion, holding 74.18% of shares as of April 2025.